文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation.

作者信息

Manson Guillaume, Brice Pauline, Herbaux Charles, Bouabdallah Kamal, Antier Chloé, Poizeau Florence, Dercle Laurent, Houot Roch

机构信息

Department of Hematology, University Hospital of Rennes, Rennes, France.

Department of Hematology, Saint-Louis Hospital, AP-HP, Paris, France.

出版信息

Haematologica. 2020 Nov 1;105(11):2664-2666. doi: 10.3324/haematol.2019.242529.

DOI:10.3324/haematol.2019.242529
PMID:33131257
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7604630/
Abstract
摘要

相似文献

[1]
Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation.

Haematologica. 2020-11-1

[2]
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.

Eur J Cancer. 2019-5-10

[3]
Brentuximab induced CD30 cutaneous lymphoma responded to anti-PD1 treatment.

J Eur Acad Dermatol Venereol. 2019-4

[4]
Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma.

Eur J Cancer. 2018-3

[5]
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma.

Cancer Med. 2020-11

[6]
Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.

Blood. 2020-12-17

[7]
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.

Oncologist. 2018-12-19

[8]
Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma.

Blood. 2018-6-21

[9]
Pembrolizumab for classical Hodgkin's lymphoma.

Lancet Oncol. 2016-8

[10]
Subacute inflammatory demyelinating polyradiculoneuropathy complicating relapsing Hodgkin lymphoma: another immune-related adverse event of the anti-PD1 therapy?

Leuk Lymphoma. 2019-2

引用本文的文献

[1]
Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma.

Blood Neoplasia. 2025-7-1

[2]
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers.

Blood Cancer J. 2025-3-26

[3]
Nivolumab plus relatlimab in patients with relapsed or progressed B-cell malignancies in RELATIVITY-022.

Blood Adv. 2025-3-3

[4]
Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan.

Int J Hematol. 2024-6

[5]
Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy.

Cancers (Basel). 2023-9-11

[6]
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.

Cancers (Basel). 2023-2-24

[7]
Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin's Lymphoma.

Cancers (Basel). 2022-6-14

[8]
Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway.

Curr Oncol Rep. 2022-11

[9]
How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents.

Hematology Am Soc Hematol Educ Program. 2021-12-10

[10]
Nivolumab in relapsed/refractory Hodgkin lymphoma: towards a new treatment strategy?

Am J Blood Res. 2021-6-15

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索